Carmine Therapeutics

Carmine Therapeutics is a biotechnology company headquartered in Cambridge, Massachusetts. Founded in 2019, the company employs 9 people. Carmine Therapeutics specializes in developing non-viral gene therapies utilizing red blood cell extracellular vesicles. Their therapies incorporate proprietary payloads, offering a novel approach to gene delivery. The company's focus lies in partnering with pharmaceutical giants like Takeda Pharmaceuticals, with whom they have secured a research alliance potentially reaching $900 million. Recognized for its groundbreaking work, Carmine Therapeutics has been named one of FierceBiotech’s Fierce 15 Biotech companies of 2020 and awarded the Bristol-Myers Squibb "Golden Ticket." The company's leadership boasts experienced figures in the biotechnology industry, including Professor Harvey Lodish, a founding member of successful biotechs Genzyme and Millennium Pharmaceuticals. For media inquiries, please contact [email protected]. Investor relations inquiries can be directed to [email protected].